Marisa Wexler, MS, senior science writer —

After hospitalization due to chronic obstructive pulmonary disease (COPD) exacerbation, patients who live in rural areas and/or have to drive long distances to get to lung specialty centers are more likely to be prescribed an inhaler therapy regimen that isn’t in line with medical guidelines. That’s according to a…

In the U.S., many people with diagnosed or probable chronic obstructive pulmonary disease (COPD) at higher risk of disease exacerbations are not receiving recommended care, a new study found. “This analysis reveals the gaps and opportunities for improvement in the identification and management of patients with COPD in the…

The U.S. Food and Drug Administration (FDA) has issued a warning letter to AstraZeneca for making false or misleading claims about Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate), its approved inhalation therapy for chronic obstructive pulmonary disease (COPD). According to the FDA, promotional material about Breztri distributed by AstraZeneca includes claims…

Verona Pharma has filed an application asking the U.S. Food and Drug Administration (FDA) to approve inhaled ensifentrine as a maintenance treatment for chronic obstructive pulmonary disease (COPD). The regulatory submission “is a significant milestone towards our goal of bringing this potential first-in-class therapy to COPD patients…

People with chronic obstructive pulmonary disease (COPD) tend to experience worsening symptoms at times when levels of pollution in their community are higher, a new U.S. study indicates. “Our findings are consistent with a growing number of studies reporting adverse effects of community-level exposure to air pollution on respiratory…

Prompt treatment with Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) after a moderate or severe chronic obstructive pulmonary disease (COPD) exacerbation can lower the risk of a future worsening episodes. That’s according to data by AstraZeneca, which markets Breztri Aerosphere, in the late-breaking abstract, “Exacerbations and Real-world Outcomes…

Among people with chronic obstructive pulmonary disease (COPD) who have emphysema, individuals who continue to smoke after being diagnosed tend to have faster progression of lung damage, a recent study reported. According to researchers, these findings imply quitting smoking may help slow lung disease progression. “We were able to…

Many people with chronic obstructive pulmonary disease (COPD) or asthma use their inhaler therapies incorrectly, according to a recent study conducted at a center in Turkey. “The misuse of inhalers has been an obstacle to both patients and clinicians for many years and unfortunately still remains a significant issue,”…

Ensifentrine, an inhaled treatment being developed by Verona Pharma, lowered the rate of exacerbations, or episodes of sudden disease worsening, across all subgroups of patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) in the Phase 3 ENHANCE-2 trial. “We are very encouraged by the meaningful and consistent reductions…

Most people with chronic obstructive pulmonary disease (COPD) who participated in a U.S. pilot program of NuvoAir’s virtual monitoring service reported a decrease in hospitalizations and a better quality of life, the company announced. NuvoAir’s COPD solution uses proprietary home monitoring devices, including a spirometer and an…